Avanos Medical Inc Dossier
Qualitative Analysis
Business overview
Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions designed to help patients get back to the things that matter. The company operates through two primary franchises: Specialty Nutrition Systems (SNS) and Pain Management & Recovery (PM&R). Its enteral feeding portfolio (such as NeoMed and CORFLO) provides vital nutrition delivery solutions from neonates to adults. Its pain management portfolio offers non-opioid therapies, including surgical pain pumps (ON-Q and ambIT) and cold/compression therapy systems (Game Ready), to manage chronic and post-surgical pain while reducing opioid dependency.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A comprehensive restructuring program initiated to optimize manufacturing, streamline the organizational footprint, rationalize product portfolios, and focus on core high-margin segments (Specialty Nutrition Systems and Pain Management & Recovery).
Expected impact: Anticipated to deliver $15 million to $20 million in incremental annualized savings by the end of 2026, supporting long-term gross margins of over 60%.
Relocating syringe manufacturing operations out of China to Mexico and Cambodia to mitigate heavy tariff burdens.
Expected impact: Mitigates a $30 million tariff expense, with 70% of production in Mexico benefiting from USMCA tariff-free provisions.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of the proprietary TKO anti-reflux needleless connector technology to strengthen the Specialty Nutrition Systems portfolio, specifically targeting Neonatal and Pediatric Intensive Care Units (NICUs and PICUs).
Financial impact: Immediately accretive to revenue growth and earnings per share, with up to $20 million in additional contingent payments tied to net sales growth.
Acquisition of a leading manufacturer of innovative radiofrequency ablation (RFA) products used to treat chronic pain, adding the RF Trident technology to complement Avanos' COOLIEF Cooled Radiofrequency offerings.
Financial impact: Immediately accretive to revenue growth, gross margins, operating margins, and EPS, with up to $7 million in additional contingent cash consideration.